STUDY OF THE VALIDATION PARAMETER “LINEARITY /CALIBRATION MODEL” OF ANALYTICAL METHODOLOGY OF QUANTITATIVE DETERMINATION OF KARDIAZOL IN BIOLOGICAL LIQUIDS FOR PHARMACOKINETIC STUDIES
DOI:
https://doi.org/10.11603/mcch.2410-681X.2019.v0.i1.10012Keywords:
Kardiazol, validation, “linearity/calibration model”, pharmacokineticsAbstract
Introduction. Preclinical and clinical trials are one of the most important stages in the development of medicinal products, the proper conduct of which ensures in the future the safety and high therapeutic effectiveness of the developed medicines. A key element of preclinical research is a variety of pharmacological methods, in which a number of analytical measurements are carried out on certain biological objects. Thus, issues related to the identification of the peculiarities of the validation process of bioanalytical methods used in preclinical pharmacological research of medicinal products and the development of standardized approaches to such validation work for original substances become relevant.
The aim of the study – to make an experimental study of the validation parameter “linearity/calibration model” for quantitative determination of Кardiazol in human plasma for pharmacokinetic studies.
Research Methods. The bioanalytical method for the determination of Кardiazol is based on HPLC/MS/MS analysis of analytes in investigated solutions obtained from plasma samples after pre-precipitation of proteins. Samples were chromatographed using Discovery C18 chromatography column, 50 × 2.1 mm, with a particle size of 5 μm and gradient elution.
Results and Discussion. When constructing a calibration curve, the following conditions must be fulfilled: for lower limit of quantitative determination, the deviation from the nominal concentration should be no more than ± 20 %; for calibration solutions with concentrations more than lower limit of quantitative determination, the deviation from the nominal concentration should be no more than ± 15 %. A linear relationship was found between the concentration and the area of the chromatographic peaks of cardiogenol in the concentration range of 1 ng/ml – 100 ng/ml. The regression equation is y = 0.0141x + -0.00146, the correlation coefficient is r2 0.9985.
Conclusion. The conclusion regarding the developed methodology according to the validation parameter “linearity/calibration model” is correct.
References
Braggio, S., Barnaby, R.J., Grosi, P., & Cugola, M. (1996). A strategy for validation of bioanalytical methods. Journal of Pharmaceutical and Biomedical Analysis, 14 (4), 375-388.
Singh, U.K., Pandey, P., & Keshri, P.K. (2000). Bioanlytical method development and validation. Biorg. Chem., 2, 34-45.
Causon, R. (1997). Validation of chromatographic methods in biomedical analysis viewpoint and discussion. J. Chromatogr. B., 689 (1), 175-180.
Sharma, A., & Rathore, S. (2012). Bioanalytical Method development and Validation of Drugs in Biological fluid. Int. J. of Pharm & Research Sci., 1 (4), 216-226.
James, C.A., Breda, M., & Frigerio, E. (2004). Bioanalytical method validation: a risk-based approach. Journal of Pharmaceutical and Biomedical Analysis, 35 (4), 887-889.
Murugan, S., Pravallika, N., Sirisha, P., & Chandrakala, K. (2013). Bioanalytical method development and validation by using LC-MS/MS. Journal of Chemical and Pharmaceutical Sciences, 6 (1), 41-45.
Perekhoda, L.O., Drapak, I.V., Suleiman, M.M., Sych, I.A., & Yaremenko, V.D. (2017). Synthesis and in silico research of derivatives of 3-allyl-4-(R-phenyl)-N-(R1-phenyl)thiazole-2-imine. Der Pharma Chemica, 9 (13), 95-98.
Drapak, I.V., Perekhoda, L.O, Demchenko, A.M., Herashchenko, I.V., & Niektiehaiev, I.O. (2017). Patent na korysnu model № 122197 Hidrobromid [3-alil-4-(41-metoksyfenil)-3N-tiazol-2-iliden]-(32-tryfluorometylfenil)aminu, shcho maye kardioprotektorni vlastyvosti [Patent for Utility Model No. 122197 Hydrobromide [3-allyl-4- (41-methoxyphenyl) -3H-thiazole-2-ylidene] - (32-trifluoromethylphenyl) amine having cardioprotective properties]. Vlasnyk – Lvivskyi natsionalnyi medychnyi universytet imeni Danyla Halytskoho – Patent for Utility Model No. 122197 Hydrobromide [3-allyl-4- (41-methoxyphenyl) -3H-thiazole-2-ylidene] - (32-trifluoromethylphenyl) amine having cardioprotective properties. The owner – Danylo Halytskyi Lviv National Medical University, a statement. 07.10.2017, Published on December 26, 2017-Jul.24 [in Ukrainian].
(2013). Validatsiya bioanaliticheskogo metoda: metod. rekomendatsii [Validation of the bioanalytical method: method. recommendations]. Kyiv: “Gosudarstvennyy ekspertnyy tsentr” [in Russian].
Logoyda, L., Korobko, D., & Kovalenko, S. (2018). The methods for determination of combination antihypertensive drugs in human plasma by HPLC MS/MS. 23nd Dubai International Pharmaceuticals & Technologies Conference & Exhibition, February, 27 – March, 01, 2018. Dubai.
Guidance for Industry. Bioanalytical Method Validation/ /Center for Drug Evaluation and Research, U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Rockvill, Maryland, May 2001.
